APP and early-onset autosomal dominant Alzheimer disease: It was also tested in a Phase 2/3 study called the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) aimed at preventing dementia in 210 people who were in the progression to Alzheimer’s disease due to an inherited autosomal-dominant mutation in APP, PSEN1, or PSEN2. 337 Gantenerumab treatment significantly reduced the amyloid loads and normalized CSF Aβ42 levels.338 However, cognitive data revealed that gantenerumab did not reach its therapeutic point.